Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia

Journal of Clinical Endocrinology and Metabolism

Volumn 87, Issue 9, 2002, Pages 4171-4176

  Saloranta, Carola ^a,b,c   Hershon, Kenneth ^a,b,c   Ball, Michele ^a,b,c   Dickinson, Sheila ^a,b,c   Holmes, David ^a,b,c  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b N Shore Diabet and Endocr Assoc   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; NATEGLINIDE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLU LIKE SYNDROME; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RELEASE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STANDARDIZATION; TREMOR; UPPER RESPIRATORY TRACT INFECTION;

ADULT; BLOOD GLUCOSE; CONTINENTAL POPULATION GROUPS; CYCLOHEXANES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN; MALE; PHENYLALANINE; TREATMENT OUTCOME;

EID: 0036736833     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2002-020068     Document Type: Article

References (16)

1. UK Prospective Diabetes Study Group 1998 Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853
2. The DCCT Research Group 1993 The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986
3. The DCCT Research Group 1997 Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 46:271-286
4. Matthews DR 1999 The natural history of diabetes-related complication: the UKPDS experience. Diabetes Obes Metab 1(Suppl 2):S7-S13
5. 1997 Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183-1197
6. American Diabetes Association 2001 Standards of medical care for patients with diabetes mellitus. Diabetes Care 24(Suppl 1):S33-S43
7. Pratley RE, Foley JE, Dunning BE 2001 Rapid acting insulinotropic agents: restoration of early insulin secretion as a physiologic approach to improve glucose control. Curr Pharm Des 7:1375-1397
8. Hollander PA, Schwartz SL, Gatlin MR, Haas SJ, Zheng H, Foley JE, Dunning BE 2001 Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care 24:983-988
9. Dunning BE, Paladini S, Gutierrez C, Deacon R, Valentin M 1999 Nateglinide improves prandial glucose excursions by restoring early insulin secretion in pre-diabetic monkeys. Diabetologia 42(Suppl 1):A4
10. Weyer C, Bogardus C, Mott DM, Pratley RE 1999 The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104:787-794
11. Hanefeld M, Dickinson S, Bouter KP, Guitard C 2000 Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diabetes Care 23:202-207
12. Horton ES, Clinkinbeard C, Gatlin M, Foley J, Mallows S, Shen S 2000 Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 23:1660-1665
13. The DCCT Research Group 1995 The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 44:968-983
14. U.K. Prospective Diabetes Study Group 1998 United Kingdom prospective diabetes study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 128:165-175
15. Dimitriadis GD, Gerich JE 1983 Importance of timing of preprandial subcutaneous insulin administration in the management of diabetes mellitus. Diabetes Care 6:374-377
16. Bruttomesso D, Pianta A, Mari A, Valerio A, Marescotti M-D, Avogaro A, Tiengo A, Delprato S 1999 Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. Diabetes 48:99-105